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Abstract
Background: Bone marrow derived stem/progenitor cell transplantation after acute myocardial infarction is safe
and effective for improving left ventricular systolic function. However, the improvement of left ventricular systolic
function is limited. This study will evaluate novel stem/progenitor cell therapy with combination cytokine
treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulating factor
(G-CSF) in patients with acute myocardial infarction.
Methods: The ‘MAGIC Cell-5-Combination Cytokine Trial’ is a multicenter, prospective, randomized, 3-arm,
controlled trial with blind evaluation of the endpoints. A total of 116 patients will randomly receive one of the
following three treatments: an intravenous darbepoetin infusion and intracoronary infusion of peripheral blood
stem cells mobilized with G-CSF (n = 58), an intracoronary infusion of peripheral blood stem cells mobilized with
G-CSF alone (n = 29), or conventional therapy (n = 29) at phase I. Patients with left ventricular ejection fraction <
45% at 6 months, in the patients who received stem cell therapy at phase I, will receive repeated cell therapy at
phase II. The objectives of this study are to evaluate the safety and efficacy of combination cytokine therapy with
erythropoietin and G-CSF (phase I) and repeated progenitor/stem cell treatment (phase II).
Discussion: This is the first study to evaluate the safety and efficacy of combination cytokine based progenitor/
stem cell treatment.
Trial registration: http://www.ClinicalTrials.gov identifier: NCT00501917.
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Recent clinical trials reported favorable effects of stem/
progenitor cell transplantation in patients with acute
myocardial infarction (AMI), suggesting that stem cell
transplantation is feasible, safe, and effective for
improvement of left ventricular (LV) systolic function
and myocardial perfusion [1-3]. Granulocyte colony-
stimulating factor (G-CSF) alone is mostly ineffective
for improvement of LV systolic function [4]. But G-
CSF is effective for stem/progenitor cell mobilization
and local delivery of mobilized stem/progenitor cell by
G-CSF improved cardiac function in patients with
myocardial infarction [2,3,5-8]. However, degree of
improvement by G-CSF based stem/progenitor cell
therapy is modest and similar to that of bone marrow
stem cell therapy. There are reasonable explanations of
limited efficacy of current stem/progenitor cell therapy
using G-CSF, such as, low homing-efficiency, poor
long-term survival of infused stem/progenitor cells,
and potential dysfunction of mobilized stem/progenitor
cells by G-CSF [9,10].
To overcome potential limitations of current stem/
progenitor cell therapy and to improve efficacy, combi-
nation treatment with multiple cytokines is introduced
in this study. Erythropoietin is a cytokine secreted by
the kidney in response to hypoxia, and regulates plasma
hemoglobin concentrations. Experimental studies
revealed that erythropoietin can protect cardiomyocytes
f r o mn e c r o t i co ra p o p t o t i cd a m a g eb yi s c h e m i a[ 1 1 ] .
Moreover, it can induce angiogenesis by stimulating
endothelial progenitor cells (EPCs) [12,13]. In preclinical
study, combination therapy with erythropoietin and
bone marrow stem cells showed better outcomes than
monotherapy either with bone marrow stem cell or ery-
thropoietin [14]. Expecting additional effects by erythro-
poietin, we have developed a novel stem/progenitor cell
treatment strategy for AMI, combining erythropoietin to
stem/progenitor cell therapy using G-CSF. Additionally
we planned to evaluate safety and efficacy of repeated
stem cell therapy in severely diseased patients who have
persistent LV dysfunction at 6 months after initial stem/
progenitor cell therapy. Here, we describe our new
treatment strategy for the first time and present the
rationale of this study by reviewing the current evidence
for a beneficial effect of G-CSF-based stem/progenitor
cell therapy and erythropoietin in patients with AMI.
Methods
Study Objectives
The objectives of the present study are (1) to evaluate
whether novel combination stem/progenitor cell therapy
can improve LV systolic function better than conven-
tional therapy and intracoronary infusion of mobilized
peripheral blood stem/progenitor cell (PBSC) by G-CSF
alone respectively; and (2) to evaluate the safety and fea-
sibility of combination use of G-CSF and darbepoetin.
The primary end point is the changes in resting LV
systolic function (ejection fraction) in patients after
AMI, measured by cardiac magnetic resonance imaging
(MRI) 6 months after primary revascularization of cul-
prit arteries and stem/progenitor cell transplantation.
T h es e c o n d a r ye n dp o i n t so ft h es t u d ya r ec h a n g eo f
wall motion score index measured by cardiac cine-MRI
or echocardiography, and the major adverse cardiac
events (MACE), defined as all cause mortality, target
lesion revascularization, rehospitalization for recurrent
ischemia or heart failure, or refractory angina. And in
case of repeated stem/progenitor cell therapy, changes
of LV ejection fraction 6 months after repeated therapy.
Study design
The ‘MAGIC Cell-5-Combination Cytokine Trial’
described here is a multicenter, prospective, randomized,
3-arm, controlled, phase 2 trial with blind evaluation of
endpoints (Figure 1).
Phase I After a successful revascularization of culprit
lesion with drug eluting stents, patients will be randomly
allocated and receive one of three treatments: (1) for the
combicytokine group (n = 58) intravenous infusion of
long acting analogue of erythropoietin, darbepoetin
(Amgen, USA) just after revascularization and an addi-
tional intracoronary infusion of PBSC mobilized with
G-CSF, (2) for the G-CSF group (n = 29) an intracoron-
ary infusion of PBSC mobilized with G-CSF alone, or
(3) for the control group (n = 29) conventional therapy.
Patients will undergo cardiac MRI within a week after
revascularization.
Phase II For the G-CSF and combicytokine groups,
patients who still have LV systolic dysfunction (LV ejec-
tion fraction < 45%) at 6 months after initial stem/pro-
genitor cell therapy, will receive repeated cell therapy as
they are assigned in phase I.
Study population
In total, 116 patients with acute ST segment elevation
acute myocardial infarction (STEMI) will be included.
Patients will be considered for participation in this study if
they meet all of the inclusion criteria and none of the
exclusion criteria in Table 1. After receiving the angiogra-
phies, patients and/or their family will be asked for their
oral informed consent by an independent coordinator; if
they agree, patients will be randomly allocated by means of
sealed envelope to one of the 3 treatment groups. After
being admitted to the coronary care unit and after revascu-
larization, patients will sign the written informed consent.
For the phase II therapy, the patients who meet the inclu-
sion criteria and their LV ejection fractions under 45% at 6
months will be eligible for the repeated cell therapy.
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Phase I
All patients will be treated, according to current practice
guidelines and standard medication for an AMI consisting
of aspirin, clopidogrel, heparin and possibly abciximab will
be administered during percutaneous coronary interven-
tion [15]. Patients randomized to the combicytokine group
will receive 4.5 ug/kg of intravenous darbepoetin (maxi-
mum: 300 ug) infusion just after revascularization. Patients
in the G-CSF group will receive placebo infusion. Infusion
of darbepoetin or placebo will be performed by double
blind manners. Patients in the control group will not
receive placebo and treated in un-blinded state.
After revascularization, patients in the combicytokine
and G-CSF group will also be treated with an intracor-
onary infusion of PBSC. Patients will receive a subcuta-
neous injection of G-CSF (Dong-A Pharmaceutical,
South Korea) at 5 ug/kg body weight twice daily for
3 days. After 3 days of G-CSF injection, mobilized PBSC
will be collected with a COBE spectra apheresis system
(COBE BCT Inc., USA) using the mononuclear cell col-
lection method. The infusion cell doses will be 2 × 10
9
Table 1 Enrollment criteria for the MAGIC Cell-5-
Combination Cytokine Trial
Inclusion criteria
Age: 18 to 80 years
Able to verbally confirm understandings of risks, benefits, and
treatment alternatives of receiving the cell therapy provides written
informed consent before any study-related procedure
ST-segment elevation acute myocardial infarction
Successful revascularization of culprit vessel
Exclusion criteria
Known hypersensitivity or contraindication to any of the following
medications:
Heparin, aspirin, clopidogrel, sirolimus, everolimus, contrast media
Uncontrolled congestive heart failure (patients with LVEF <20% or
Killip class II, III or those with cardiogenic shock)
Uncontrolled myocardial ischemia (repeated chest pain or dyspnea
after revascularization)
Uncontrolled ventricular arrhythmia
History of malignancy
Serious hematologic disease
Current infectious disease needs antibiotics therapy
Creatinine level >2.0 mg/dL or dependence on dialysis
LVEF, left ventricular ejection fraction.
Figure 1 Flow chart demonstrating scheduling during the MAGIC Cell-5-Combination Cytokine Trial.
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m u mt a r g e tc e l ld o s eo f7×1 0
6 CD34-positive cells.
Collected autologous PBSC will be selectively infused to
infarct-related artery via over-the-wire balloon catheter,
as previously described
2. Placebo will not be applied to
the control group.
Phase II
Open follow-up will be made after 6 months follow-up
evaluation. Phase II trial is considered for the patients in
the G-CSF and combicytokine group, whose LV ejection
fraction is under 45% at 6 months evaluated by cardiac
MRI. Eligible patients will be asked to receive repeated
stem/progenitor cell therapy as they were assigned in
phase I. If the patients agree with the repeated therapy,
darbepoetin or placebo injection will be given and then
stem cell mobilization followed by intracoronary infu-
sion will be performed under the same way, as described
in the previous paragraph.
Cardiac MRI
Cardiac contrast enhanced MRI (Sonata 1.5T, Siemens,
Germany) will be performed after revascularization
within a week before PBSC infusion. After localization
of the heart, 8 to 11 contiguous short-axis slices of
8m mt h i c k n e s sw i t hg a po f2m mw i l lb ea c q u i r e dt o
cover entire left ventricle from base to apex. After intra-
venous application of gadolinium-diethylene-triamine
penta-acetate (GE healthcare, USA), late enhancement
imaging will be performed with a phase-sensitive inver-
sion recovery sequence. LV ejection fraction and LV
volumes will be calculated with ARGUS software
(Siemens). Regional LV function will be assessed by
determining systolic wall motion with a 17-segment
model, as proposed by the American Heart Association
[16]. Segmental wall thickening will be judged visually
as falling into 1 of the following semiquantitative cate-
gories: normokinetic (1), hypokinetic (2), akinetic (3) or
dyskinetic (4). Segmental extent of late enhancement
will be scored as one of the following: 0%, 1 to 25%, 26
to 50%, 51 to 75%, 76 to 100% of either volume extent
or transmural extent.
Patient follow-up
Follow-up cardiac MRIs and coronary angiographies for
all patients will be performed 6, and 24 months after
AMI (Figure 1). Additional cardiac MRI evaluation will
be performed 6 months after repeated stem cell therapy.
Clinical follow-ups (including patient interviews, physi-
cal assessments, and clinical laboratory tests) will be
conducted every 2-4 months throughout the study per-
iod. During follow up all patients will be treated, accord-
ing to current practice guidelines, with antiplatelet
agents, a statin, a beta-blocker, and an angiotensin con-
verting enzyme inhibitor or angiotensin-receptor
blocker, unless these agents are contraindicated [17]. If
patients who were enrolled in this study but did not
complete stem cell infusion drop out, we will follow
them at least till 1 month after index hospitalization.
Sample size calculation and statistical analysis
This study was designed to detect differences in changes
of LV ejection fraction at 6 months relative to baseline
between the combicytokine group and two other groups
respectively. Sample size was calculated on the premise
that we would assign patients to the combicytokine
groups and two comparator group (the control and
G-CSF group) at a ratio of 2:1 respectively to adequately
evaluate the effects of new treatment with combicyto-
kine. We hypothesized that combination therapy with
darbepoetin can induce 2.4% additional improvement of
LV ejection fraction than the G-CSF group, which was
60% improvement over reference value observed in
small pilot study and our previous study [3,18]. This
study has 80% power to detect a 5% difference between
treatment groups, assuming a 1-sided alpha of 0.05.
With an estimated drop-out rate of 10%, we will need
approximately 29 patients in the control and G-CSF
group respectively and 58 patients in the combicytokine
group.
The primary and secondary endpoints will be analyzed
on modified intention-to-treat analysis. For evaluation of
primary and secondary efficacy endpoints, patients who
completed stem cell infusion will be included. For eva-
luation of safety endpoints, all patients who signed the
w r i t t e ni n f o r m e dc o n s e n ta n dw e r er a n d o m i z e dt o
receive any part of active treatment (darbepoetin/pla-
cebo infusion and G-CSF, PBSC infusion) will be
included in the analysis.
Baseline characteristics of study patients will be sum-
marized in terms of frequencies and percentages for
categorical variables and by means with standard devia-
tions for continuous variables. Categorical variables will
be compared with Chi-square or Fisher’se x a c tt e s t s .
Continuous variables showing normal distribution will
be compared using the student t-test whereas those
showing non-normal distribution will be compared
using the nonparametric Wilcoxon 2-sample test
between the combi-cytokine group and two compara-
tors, the G-CSF group and the control group, respec-
tively. Bonferroni’s correction will be applied to the
repeated comparisons. Significance will be defined as
p value < 0.05.
Trial Organization
Executive committee
The executive committee will be composed of the study
chairperson and the principal investigators of the inves-
tigating centers. This committee is responsible for
Kang et al. Trials 2011, 12:33
http://www.trialsjournal.com/content/12/1/33
Page 4 of 7overseeing the administrati v ep r o g r e s so ft h es t u d ya n d
will approve the final trial design and protocol issued to
the data and safety monitoring board (DSMB) and the
clinical sites. This committee will also be responsible for
reviewing the final results, determining the methods of
presentation and publication, and selecting secondary
projects and publications by members of the steering
committee. The executive committee also holds the
r i g h tt om o d i f yo rs t o pt h es t u d yp r e m a t u r e l yb a s e do n
recommendations from the DSMB.
Steering committee
The steering committee will be composed of the prin-
cipal investigators from the centers participating in
this trial. The committee is responsible for the day-to-
day administrative management of the trial and will
meet on a regular basis to monitor subject enrollment,
clinical site progress, and protocol compliance. It will
be the responsibility of the steering committee to pro-
vide assistance and education to individual sites and
researchers for trial management, record keeping, and
reporting requirements. The steering committee will
prepare reports to be reviewed by the executive
committee.
Data safety monitoring board
The DSMB will be composed of general and interven-
tional cardiologists, and a biostatistician. The DSMB will
function in accordance with applicable regulatory guide-
lines. The board members are independent and will not
be participating in the trial. The DSMB committee will
review the safety data from this study and make recom-
mendations based on safety analyses of serious adverse
events, protocol deviations, and 30-day follow-up
reports. The frequency of the DSMB meetings will be
determined prior to commencement of the study. Addi-
tionally, the DSMB may call a meeting at any time if
there is reason to suspect that safety is an issue. The
DSMB is responsible for making recommendations
regarding any safety or compliance issues throughout
t h ec o u r s eo ft h es t u d ya n dm a yr e c o m m e n dt h a tt h e
executive committee modify or stop the study. However,
all final decisions regarding study modifications rest
with the executive committee. All cumulative safety data
will be reported to the DSMB and reviewed on an
ongoing basis throughout enrollment and follow-up per-
iods to ensure patient safety. Every effort will be made
to allow the DSMB to conduct an unbiased review of
patient safety information. Before the DSMB’sf i r s t
review of the data, the DSMB charter will be drafted.
The DSMB will develop a consensus understanding of
all trial end points and definitions used in the event
adjudication process. All DSMB reports will remain
strictly confidential but will be made available to the
regulatory body upon request.
Clinical event adjudication committee
The clinical event adjudication committee (CEAC) is
composed of interventional and noninterventional cardi-
ologists who are not participants in the study. The
CEAC is charged with the development of specific cri-
teria used for the categorization of clinical events and
clinical endpoints in the study, based on study protocols.
At the onset of the trial, the CEAC will establish explicit
rules outlining the minimum amount of data required
and the algorithm to follow when classifying a clinical
event. All members of the CEAC will be blinded to the
primary results of the trial. The CEAC will meet regu-
larly to review and adjudicate all clinical events in which
the required minimum data are available. The commit-
tee will also review and rule on all deaths that occur
throughout the trial.
Data coordination and site management
Data coordination and site management services will be
performed by dedicated research nurses from the clini-
cal trials center at Seoul National University Hospital.
The designated trial monitors, at appropriate intervals,
will review investigational data for accuracy and comple-
teness and ensure compliance with the protocols.
Ethical approval
This study has been approved by the institutional review
board of Seoul National University Hospital.
Discussion
Erythropoietin has several non-erythropoietic functions.
Erythropoietin was found to be a potent stimulus for
the mobilization of EPCs into peripheral blood, which
was associated with neovascularization of ischemic tis-
sue [18]. A pilot study of 22 patients with acute STEMI
evaluated the safety and tolerability of a single-bolus
300 ug darbepoetin treatment administered before pri-
mary PCI [19]. No adverse events were noted during the
30-day follow-up. At 72 hours after darbepoetin admin-
istration, CD34
+/CD45
- cell count significantly increased
in darbepoetin group but not in the control. This result
suggests that darbepoetin treatment after myocardial
infarction stimulates EPC mobilization.
Erythropoietin and its receptor have also been found
in neuronal, vascular, and myocardial tissue [20]. Ery-
thropoietin and its receptor exert antiapoptotic actions,
as well as pro-angiogeneic and anti-inflammatory effects
[21-23]. Additionally, it increases coronary flow and
enhances the synthesis and bioavailability of constitutive
nitric oxide, via endothelial nitric oxide synthase tran-
scription and activation [24]. Recently Brunner et al
reported that erythropoietin treatment has improved
homing of bone marrow cells into the infarcted myocar-
dium, via the CXCR-4/SDF-1-axis [25]. However based
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fective to improve cardiac function after AMI.
Suh et al reported that high dose single bolus infusion
of erythropoietin failed to reduce infarct size but that it
was safe in patients with AMI [26]. Ott et al reported
that epoietin-beta infusion just after primary revasculari-
zation of STEMI did not improve LV function and
infarct size and that there was a trend towards a higher
rate of adverse events in the erythropoietin-treated
group [27]. Thus, the effort to measure the safety and
efficacy of erythropoietin treatment in myocardial
infarction patients is still continuing; for instance, the
on-going EPAMINONDAS trial is investigating whether
erythropoietin treatment can safely reduce infarct size in
STEMI patients [28].
Although erythropoietin alone is insufficient to
improve cardiac function in AMI, its cytoprotective and
stem cell mobilizing effects can be synergistically inte-
grated to G-CSF based stem/progenitor cell therapy.
Effects of G-CSF and erythropoietin are mediated by
activation of their own specific receptors. Thus we
hypothesized that a combination therapy of G-CSF and
darbepoetin will enhance the therapeutic efficacy of
stem cell therapy. The ‘MAGIC Cell-5-combination
cytokine Trial’ will allow us evaluate efficacy and safety
of new combination strategy. We hope that new strategy
proposed here will combine complementary beneficial
effects from each of these treatments and will prevent
ischemic cardiomyopathy in patients with myocardial
infarctions.
Regarding the efficacy of the repeated stem/progenitor
cell therapy in myocardial infarction, there have been
mixed results [29,30]. With the phase II of this trial, we
will evaluate whether repeated PBSC therapy is safe, fea-
sible, and effective for improving cardiac function. In
our study, the repeated cell therapy will be given at
6 months after AMI. The optimal timing of repeated
stem cell therapy is unknown yet, thus our study may
be able to give insight about this issue.
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